DAWN CALABRESE: Open Payments
NPI 1720587017 · MANAHAWKIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$306 in 16 payments from 9 companies in 2025. Trend: 2023 $261 · 2024 $568 · 2025 $306
Food & beverage: $306
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $69 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Janssen Biotech, Inc. | 2 | $40 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| QOL Medical, LLC | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| GENZYME CORPORATION | 1 | $18 |
| GlaxoSmithKline, LLC. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
Products named: REZDIFFRA, CREON, TREMFYA, XIFAXAN, Sucraid, ENTYVIO, LINZESS, DUPIXENT.
Industry payments across NJ — which companies pay providers there.
